TSX and OTC: MPVDTORONTO and NEW YORK, June 15, 2026 /PRNewswire/ -- Mountain Province Diamonds Inc. ("Mountain Province" or the "Company") (TSX: MPVD) and (OTC: MPVD) announces today that it has completed...
Mark Bishop Appointed Chief Monetization Officer, Blue Ant Rights & Streaming; Matt Hornburg Appointed Chief Content Officer, Blue Ant Studios TORONTO, June 15, 2026 /CNW/...
CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- Peyto Exploration & Development Corp. (TSX: PEY) ("Peyto") confirms that the monthly dividend with respect to June 2026 of $0.12 per common share is to be paid on July 15, 2026, for shareholders of record on June 30, 2026.
FRISCO, TX, June 15, 2026 (GLOBE NEWSWIRE) -- Comstock Resources, Inc. (NYSE: CRK) announced today that it has sold a minority equity interest in Comstock's midstream subsidiary, Pinnacle Gas Services LLC ("Pinnacle"), to certain funds managed by Sixth Street, a leading global investment firm.
NINGBO, China, June 15, 2026 (GLOBE NEWSWIRE) -- PN Smart Energy Limited (“PN Smart” or the “Company”) (NASDAQ: PN), a global independent power provider (IPP) focused on the development of clean power stations, critical energy materials, and intelligent energy infrastructure, today announced its official name change of Skycorp Solar Group Limited to PN Smart Energy Limited effective June 12, 2026.
TORONTO, June 15, 2026 (GLOBE NEWSWIRE) -- International Petroleum Corporation (IPC) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce first oil has been achieved at Phase 1 of the Blackrod project, ahead of schedule and on budget.
International Petroleum Corporation (IPC) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce first oil has been achieved at Phase 1 of the Blackrod project, ahead of schedule and on budget.
MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI
MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI
– ETHY-001 produced complete blockade of autoantibody-mediated TSHR activation across all patient serum samples tested, demonstrating breadth and consistency of effect –
NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- PAVS (NASDAQ:PAVS) (the "Company"), a consumer products and digital commerce solutions company, today announced that it has entered into a definitive agreement with certain institutional investors for a registered direct offering of an aggregate of 50,000,000 Class A ordinary shares (or pre-funded warrants to purchase Class A ordinary shares in lieu thereof) at a purchase price of $0.20 per share. The gross proceeds to the Company from the offering are expected to be approximately $10 million, before deducting offering expenses.
After Decades of Addiction, Baltimore Woman Reclaims Her Future as Program's 100th Graduate BALTIMORE, June 15, 2026 /PRNewswire/ -- Three years ago, Danielle Clubb...
Strategic advisory group formed to position brand for financial stability and long-term growthDALLAS, June 15, 2026 /PRNewswire/ -- Twin Peaks Restaurant today announced that...